[go: up one dir, main page]

WO2024033278A1 - Process for manufacturing an antibiotic macrocyclic peptide - Google Patents

Process for manufacturing an antibiotic macrocyclic peptide Download PDF

Info

Publication number
WO2024033278A1
WO2024033278A1 PCT/EP2023/071759 EP2023071759W WO2024033278A1 WO 2024033278 A1 WO2024033278 A1 WO 2024033278A1 EP 2023071759 W EP2023071759 W EP 2023071759W WO 2024033278 A1 WO2024033278 A1 WO 2024033278A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
palladium
equivalents
process according
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/071759
Other languages
French (fr)
Inventor
Raphael BIGLER
Fritz Theodor BLISS
Serena Maria FANTASIA
Fabienne Roxane HOFFMANN-EMERY
Ernesto Santandrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Hoffmann La Roche Inc filed Critical F Hoffmann La Roche AG
Priority to KR1020257003548A priority Critical patent/KR20250049274A/en
Priority to IL317277A priority patent/IL317277A/en
Priority to AU2023322412A priority patent/AU2023322412A1/en
Priority to JP2025507242A priority patent/JP2025526023A/en
Priority to EP23753892.1A priority patent/EP4568984A1/en
Priority to CN202380057957.7A priority patent/CN119677765A/en
Publication of WO2024033278A1 publication Critical patent/WO2024033278A1/en
Priority to MX2025001261A priority patent/MX2025001261A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4- Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2- thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22- yl]benzoic acid (I), or a pharmaceutically acceptable salt thereof.
  • the invention further relates to certain synthetic intermediates that are useful for the novel process according to the invention.
  • the process according to the invention is particularly suitable for large-scale manufacturing of the compound of formula (I) under GMP conditions.
  • the compound of formula (I) is a potent antibiotic with selective action against Acinetobacter baumannii, as discussed in WO2019206853.
  • the compound of formula (I) is also known under the INN zosurabalpin (WHO Drug Information, Vol.36, No.2, 2022).
  • WO2019206853 discloses a laboratory scale synthesis of the compound of formula (I), which relies on a Suzuki coupling reaction that is characterized by a high catalyst loading (about 20 mol%) and a relatively high amount of a boronic acid building block (about 1.5 equivalents).
  • the high catalyst loading in addition to generating high costs, also leads to CNE/13.07.2023 palladium impurities in the final product that are difficult to remove.
  • the use of high amounts of boronic acid results in the formation of organic impurities.
  • the process disclosed in WO2019206853 involves the use of the toxic solvent dioxane, and relies on chromatography to purify certain intermediates, as well as the final product.
  • the process for making the compound of formula (I) as described in WO2019206853 is not well suited for an industrial scale synthesis of said compound of formula (I). Accordingly, there is a high unmet need for a new process for manufacturing the compound of formula (I), in order to provide patients with this new treatment option for infections with Acinetobacter baumannii and resulting diseases. Summary of the Invention The present invention provides an improved process for manufacturing the compound of formula (I), which overcomes the problems outlined above. The present invention also provides certain synthetic intermediates that are useful in the new process.
  • palladium catalyst refers to any palladium catalyst that enables the reaction of aryl bromide 1 as described herein with (4-carbomethoxyphenyl)boronic acid (2) to afford compound 3 as defined herein on an industrial scale.
  • the palladium catalyzed reaction according to the invention requires a zero valent palladium species (Pd(0)).
  • Pd(0) zero valent palladium species
  • Exemplary catalytically active Pd(0) species may be applied directly or may be formed in situ from a palladium source in combination with a phosphine ligand.
  • the palladium catalyst is a preformed palladium catalyst.
  • preformed catalytically active Pd(0) reagents include: Pd(PPh3)4 and Pd(L)2, wherein L is selected from PBu 3 , AmPhos, CPhos, RuPhos, and SPhos.
  • [PdI(L)]2 (L PtBu3, AmPhos).
  • Examples of palladium sources that form a palladium catalyst in situ in combination with a suitable ligand include: palladium bis(dibenzylideneacetone) (Pd(dba) 2 ), (Pd 2 (dba) 3 ), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh 3 ) 2 Cl 2 ), palladium acetate (Pd(OAc) 2 , palladium trifluoracetate (Pd(TFA)2), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)- palladium(II) dichloride (PdCl 2 (CH 3 CN
  • ligands that form palladium catalysts in situ in combination with a palladium source described above include: mono or diphosphines such as PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf.
  • mono or diphosphines such as PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf.
  • salt refers to any kind of salts formed by reacting the compounds disclosed herein with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, N-acetylcystein and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid
  • organic acids such as acetic acid, propionic acid, glycolic acid,
  • salts may also be prepared by addition of an inorganic base or an organic base to the free acid.
  • Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
  • Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like.
  • the present invention provides a process for manufacturing compound 3, or a salt thereof, 3 comprising: (a) reacting aryl bromide 1 + with (4-carbomethoxyphenyl)boronic acid (2) in the presence of a palladium catalyst and a base, to afford said compound 3.
  • the present invention provides a process for manufacturing compound 3, or a salt thereof, 3 comprising: (a) reacting aryl bromide 1 + with (4-carbomethoxyphenyl)boronic acid (2) in the presence of a palladium catalyst and a base in an aromatic solvent, to afford said compound 3; wherein said palladium catalyst is selected from: i) a preformed catalyst selected from Pd(PPh 3 ) 4 , Pd(L 1 ) 2 , [Pd(L 1 )XCl], [Pd(L 1 )X]trifluoromethanesulfonate, [Pd(L 1 )(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L 1 )(2-(2′-amino-1,1′-biphenyl)]methanesulfonate, [Pd(L 1 )(2-(2′- methylamino-1,1′-bipheny
  • said palladium catalyst is selected from: i) a preformed catalyst selected from Pd(PPh3)4, Pd(L 1 )2, [Pd(L 1 )XCl], [Pd(L 1 )X]trifluoromethanesulfonate, [Pd(L 1 )(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L 1 )(2-(2′-amino-1,1′-biphenyl)]methanesulfonate, [Pd(L 1 )(2-(2′-methylamino- 1,1′-biphenyl)]methanesulfonate, [Pd(L 1 )(2-(2-aminoethyl)phenyl)Cl], Pd(L 2 )Cl2, Pd(L 2 )2Cl2, and [PdI(L 3 )]2; where
  • said palladium catalyst is selected from Pd(PPh3)4, Pd(L 1 )2, [Pd(L 1 )XCl], [Pd(L 1 )X]trifluoromethanesulfonate, [Pd(L 1 )(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L 1 )(2-(2′- amino-1,1′-biphenyl)]methanesulfonate, [Pd(L 1 )(2-(2′-methylamino-1,1′- biphenyl)]methanesulfonate, [Pd(L 1 )(2-(2-aminoethyl)phenyl)Cl], Pd(L 2 )Cl2, Pd(L 2 )2Cl2, and [PdI(L 3 )]2; wherein X is selected from allyl, 2-buteny
  • said palladium catalyst is formed in situ from: i) a palladium source selected from palladium bis(dibenzylideneacetone) (Pd(dba)2), (Pd 2 (dba) 3 ), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh 3 ) 2 Cl 2 ), palladium acetate (Pd(OAc) 2 , palladium trifluoracetate (Pd(TFA) 2 ), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)-palladium(II) dichloride (PdCl 2 (CH 3 CN) 2 ), cyclopentadien
  • said mono- and diphosphine ligands are selected from PtBu3, PAd 3 , AmPhos, cataCXiumA, PtBu 2 Bu, PtBu 2 Ph, PtBu 2 -p-C 6 H 4 CF 3 , cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf.
  • said palladium catalyst is selected from Pd(PPh 3 ) 4 , CPhosPdG3, Pd 2 (dba) 3 + CPhos, and PdCl 2 (dtbpf).
  • the palladium catalyst PdCl2(dtbpf) works particularly well in the Suzuki coupling according to the invention.
  • the Suzuki coupling with PdCl 2 (dtbpf) requires only a very low catalyst loading (2 mol% or less) and a small excess of boronic acid 2, which results in reduced amount of contamination of the final product with palladium and organic impurities, reduced cost and reduced waste.
  • said palladium catalyst is PdCl 2 (dtbpf).
  • said palladium catalyst is present in an amount of 1 mol% to 10 mol% relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 1 mol% to 5 mol% relative to aryl bromide 1. In a preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 1 mol% to 3 mol% relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 2 mol% relative to aryl bromide 1.
  • said palladium catalyst is PdCl 2 (dtbpf) and is present in an amount of 1 mol% to 10 mol% relative to aryl bromide 1.
  • said palladium catalyst is PdCl2(dtbpf) and is present in an amount of 1 mol% to 5 mol% relative to aryl bromide 1.
  • said palladium catalyst is PdCl 2 (dtbpf) and is present in an amount of 1 mol% to 3 mol% relative to aryl bromide 1.
  • said palladium catalyst is PdCl 2 (dtbpf) and is present in an amount of 2 mol% relative to aryl bromide 1.
  • said base is selected from inorganic bases and alcoholates.
  • said base is selected from Na2CO3, Ba(OH)2, K3PO4, Cs2CO3, K2CO3, TlOH, KF, CsF, Bu4F, and NaOH.
  • said base is selected from K3PO4 and K2CO3.
  • step (a) of the process according to the invention said base is K 3 PO 4 .
  • said base is K2CO3.
  • step (a) of the process according to the invention 1 to 4 equivalents of said base relative to aryl bromide 1 are used.
  • step (a) of the process according to the invention 1 to 3 equivalents of said base relative to aryl bromide 1 are used.
  • step (a) of the process according to the invention 1 to 2 equivalents of said base relative to aryl bromide 1 are used.
  • step (a) of the process according to the invention 1.5 equivalents of said base relative to aryl bromide 1 are used.
  • One advantage of the Suzuki coupling of process step (a) according to the invention is that it performs very well in toluene, as opposed to the toxic dioxane described in WO2019206853. This is of particular importance when conducting the reaction on an industrial scale and in view of the fact that the final antibiotic product of formula (I) is for administration to mammals, where traces of toxic solvents are not acceptable.
  • step (a) is conducted in an aromatic solvent.
  • said aromatic solvent is selected from toluene, xylenes (o-xylene, p- xylene, m-xylene or a mixture thereof), ethylbenzene, anisole, cumene, and cymene.
  • said aromatic solvent is toluene. It was found that the methyl ester moiety of boronic acid building block 2 is prone to hydrolysis under the reaction conditions used. However, it was surprisingly found that adding water to the reaction mixture prevents said hydrolysis, allowing to employ fewer equivalents of this building block. Thus, in one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water.
  • step (a) of the process according to the invention the process is conducted in the further presence of 1 to 30 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 1 to 20 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 5 to 25 equivalents of water relative to aryl bromide 1. In a preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 10 to 25 equivalents of water relative to aryl bromide 1.
  • step (a) of the process according to the invention is conducted in the further presence of 12.5 to 25 equivalents of water relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 25 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 5 to 15 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 10 to 15 equivalents of water relative to aryl bromide 1.
  • step (a) of the process according to the invention the process is conducted in the further presence of 12.5 equivalents of water relative to aryl bromide 1.
  • the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-8 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-7 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • step (a) of the process according to the invention the process is conducted in the further presence of water, wherein the water is continuously added over a period of 3-6 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • step (a) of the process according to the invention the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-5 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • step (a) of the process according to the invention the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-4 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • step (a) of the process according to the invention the process is conducted in the further presence of water, wherein the water is continuously added over a period of 6 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • step (a) of the process according to the invention the process is conducted in the further presence of water, wherein the water is continuously added over a period of 3 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base.
  • the new Suzuki coupling according to the invention allows the use of less equivalents of boronic acid 2 compared to the amound of boronic acid that is used in the process described in WO2019206853.
  • 1 to ⁇ 1.5 equivalents of boronic acid 2 are used relative to aryl bromide 1.
  • step (a) of the process according to the invention 1 to 1.4 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1 to 1.3 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1.05 to 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1 to 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1.
  • step (a) of the process according to the invention 1 to 1.1 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, 1.05 equivalents of boronic acid 2 are used relative to aryl bromide 1. If desired, the level of palladium contamination of compound 3 may be reduced, typically to a level of ⁇ 10 ppm, by treating compound 3 with N-acetylcysteine or ammonium pyrrolidinedithiocarbamate in situ.
  • the process for manufacturing compound 3, or a salt thereof, according to the invention optionally further comprises: (b) adding ammonium pyrrolidinedithiocarbamate or an aqueous solution of N- acetylcysteine to the reaction mixture obtained from step (a). In one embodiment, the process for manufacturing compound 3, or a salt thereof, according to the invention optionally further comprises: (b) adding an aqueous solution of N-acetylcysteine to the reaction mixture obtained from step (a). In one embodiment, the process for manufacturing compound 3, or a salt thereof, according to the invention optionally further comprises: (b) adding ammonium pyrrolidinedithiocarbamate to the reaction mixture obtained from step (a).
  • the present invention provides a process for manufacturing compound 4, or a salt thereof, comprising steps (a) and (b) as described herein, and further comprising: (c) reacting compound 3 described herein with sodium hydroxide to afford said compound 4.
  • step (c) is performed in a solvent being an alcohol, preferably in methanol.
  • the present invention provides a process for manufacturing compound 4, or a salt thereof, comprising steps (a) and (b) as described herein, and further comprising: (c) reacting compound 3 according to claim 1 with 2 to 10 equivalents, preferably 3 to 8 equivalents, more preferably 4 to 7 equivalents, in particular 7 equivalents of sodium hydroxide to afford said compound 4, wherein said sodium hydroxide is added as a 5% w/w to 30% w/w, preferably 10% w/w to 20% w/w, in particular a 16% w/w aqueous solution to a solution of compound 3 in an alcoholic solvent or a mixture of water and an alcoholic solvent.
  • said alcoholic solvent is methanol.
  • the process for manufacturing compound 4 according to the invention optionally further comprises: (d) crystallizing said compound 4.
  • said crystallizing of said compound 4 is crystallizing of said compound 4 from a mixture of an alcohol and acetone.
  • said alcohol is selected from 2-propanol and 1-propanol.
  • said alcohol is 1-propanol.
  • the present invention provides a process for manufacturing the compound of formula (I), or a pharmaceutically acceptable salt thereof, comprising process steps (a)-(d) described herein, and further comprising: (e) reacting compound 4 described herein with an acid, to afford said compound of formula (I).
  • said acid is hydrochloric acid.
  • step (e) is performed in a solvent mixture selected from acetone/water, THF/water, and acetonitrile/water.
  • 2 to 6 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention.
  • step (e) of the process according to the invention 3 to 5 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention.
  • 4 to 5 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention.
  • 3.5 to 4.5 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention.
  • 4 to 4.1 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention.
  • 4 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention.
  • step (e) of the process according to the invention is performed between room temperature and reflux. In a preferred embodiment, step (e) of the process according to the invention is performed between 30 °C and reflux. In a further preferred embodiment, step (e) of the process according to the invention is performed between 35 °C and 65 °C. In a particularly preferred embodiment, step (e) of the process according to the invention is performed between 35 °C and 60 °C. In a further aspect, the present invention provides the use of the process for manufacturing compound 3 described herein in the manufacture of the compound of formula (I).
  • the present invention provides the use of the process for manufacturing compound 4 described herein in the manufacture of the compound of formula (I).
  • Compounds of the Invention relates to certain synthetic intermediates that are useful for manufacturing the novel antibiotic of formula (I) described herein.
  • the present invention also relates to certain compounds when manufactured according to the novel chemical processes described herein.
  • the present invention provides a compound, which is tert- butyl 3-[[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-22-(4-methoxycarbonylphenyl)-16-methyl-12,15,18-trioxo- 2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-17- yl]methyl]indole-1-carboxylate (3), or a salt thereof .
  • the present invention provides a compound, which is 4-[(11S,14S,17S)- 14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert-butoxycarbonylamino)propyl]-17-(1H- indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22-yl]benzoic acid (4), or a salt thereof .
  • the present invention relates to compound 3 when manufactured according to the processes for manufacturing compound 3 described herein. In a further aspect, the present invention relates to compound 3 when manufactured according to the processes for manufacturing compound 3 described herein. In a further aspect, the present invention relates to the compound of formula (I) when manufactured according to the processes for manufacturing the compound of formula (I) described herein. In a further aspect, the present invention relates to the use of compound 3 described herein in the manufacture of the compound of formula (I). In a further aspect, the present invention relates to the use of compound 4 described herein in the manufacture of the compound of formula (I). Examples The invention will be more fully understood by reference to the following examples. The claims should not, however, be construed as limited to the scope of the examples.
  • the organic layer was treated with activated charcoal at room temperature.
  • the mixture was distilled under reduced pressure an the solvent was swapped to methanol and concentrated to a final volume of 80 ml.
  • Methanol (221 ml, 7.4 vol) and water (70 ml, 2.3vol) are added.
  • the mixture is heated to 50°C and 32% w/w aq.
  • sodium hydroxide (25.0 g, 200.0 mmol, 7.0 eq) is added.
  • the mixture is stirred for 5h and then cooled to 20°C.
  • Methanol is distilled off under reduced pressure.
  • Example 1a Preparation of 4-[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia- 4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22- yl]benzoic acid
  • Ammonium pyrrolidinedithiocarbamate (237 mg, 1.43 mmol, 0.3 eq) is added. The mixture was stirred for at least 1 h at 85-90°C, then the phases were split. The organic phase was extracted with water. The organic layer was distilled under reduced pressure and methanol (12.5 ml, 2.5 vol) is added. The mixture is cooled to 40°C. A 16% w/w aqueous soludion of sodium hydroxide (8.33 g, 33.33 mmol, 7.0 eq) is added. The mixture is stirred for at least 5 h and then cooled to 20°C.
  • a 35% w/w aqueous solution of citric acid (13.07 g, 23.81 mmol, 5.0 eq) is charged to the residue at 20°C and the mixture is distilled under reduced pressure.
  • the residue is extracted with ethyl acetate.
  • the organic phase is extracted with water, dried over sodium sulfate and diluted with ethyl acetate (15 ml).
  • the solution is heated to 60°C and stirred for ca.1h.
  • the resulting suspension is cooled in 12h to 0°C and stirred at least 2h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)

Abstract

The invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (I), or a pharmaceutically acceptable salt thereof. The invention further relates to certain synthetic intermediates that are useful for the novel process according to the invention. The process according to the invention is particularly suitable for large-scale manufacturing of the compound of formula (I) under GMP conditions.

Description

F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland Case: P37469 PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE Field of the Invention The invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4- Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2- thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22- yl]benzoic acid (I), or a pharmaceutically acceptable salt thereof.
Figure imgf000002_0001
The invention further relates to certain synthetic intermediates that are useful for the novel process according to the invention. The process according to the invention is particularly suitable for large-scale manufacturing of the compound of formula (I) under GMP conditions. Background of the Invention The compound of formula (I) is a potent antibiotic with selective action against Acinetobacter baumannii, as discussed in WO2019206853. The compound of formula (I) is also known under the INN zosurabalpin (WHO Drug Information, Vol.36, No.2, 2022). WO2019206853 discloses a laboratory scale synthesis of the compound of formula (I), which relies on a Suzuki coupling reaction that is characterized by a high catalyst loading (about 20 mol%) and a relatively high amount of a boronic acid building block (about 1.5 equivalents). The high catalyst loading, in addition to generating high costs, also leads to CNE/13.07.2023 palladium impurities in the final product that are difficult to remove. Similarly, the use of high amounts of boronic acid results in the formation of organic impurities. Furthermore, the process disclosed in WO2019206853 involves the use of the toxic solvent dioxane, and relies on chromatography to purify certain intermediates, as well as the final product. In summary, the process for making the compound of formula (I) as described in WO2019206853 is not well suited for an industrial scale synthesis of said compound of formula (I). Accordingly, there is a high unmet need for a new process for manufacturing the compound of formula (I), in order to provide patients with this new treatment option for infections with Acinetobacter baumannii and resulting diseases. Summary of the Invention The present invention provides an improved process for manufacturing the compound of formula (I), which overcomes the problems outlined above. The present invention also provides certain synthetic intermediates that are useful in the new process. Detailed Description of the Invention Definitions Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims and the abstract), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims and the abstract), or to any novel one, or any novel combination, of the steps of any method or process so disclosed. The term “palladium catalyst” as used herein refers to any palladium catalyst that enables the reaction of aryl bromide 1 as described herein with (4-carbomethoxyphenyl)boronic acid (2) to afford compound 3 as defined herein on an industrial scale. The palladium catalyzed reaction according to the invention requires a zero valent palladium species (Pd(0)). Exemplary catalytically active Pd(0) species may be applied directly or may be formed in situ from a palladium source in combination with a phosphine ligand. In some embodiments, the palladium catalyst is a preformed palladium catalyst. Examples of preformed catalytically active Pd(0) reagents include: Pd(PPh3)4 and Pd(L)2, wherein L is selected from PBu3, AmPhos, CPhos, RuPhos, and SPhos. Further examples of preformed palladium catalysts include: [Pd(L)XCl] (L = ligand as defined above, X = allyl, 2-butenyl, 2-methylallyl, 1-phenylallyl, p-tert-butylindenyl); [Pd(L)X]trifluoromethanesulfonate (L = ligand as defined above, X = as defined above), [Pd(L)(2-(2′-amino-1,1′-biphenyl)Cl] (L = as defined above); [Pd(L)(2-(2′-amino-1,1′-biphenyl)]methanesulfonate (L = as defined above), [Pd(L)(2-(2′-methylamino-1,1′-biphenyl)]methanesulfonate (L = as defined above), [Pd(L)(2-(2-aminoethyl)phenyl)Cl] (L = as defined above), PdLCl2, PdL2Cl2 (L =PtBu3, AmPhos, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3)2, dppf, dcypf, dippf, dtbpf. [PdI(L)]2 (L = PtBu3, AmPhos). Examples of palladium sources that form a palladium catalyst in situ in combination with a suitable ligand include: palladium bis(dibenzylideneacetone) (Pd(dba)2), (Pd2(dba)3), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), palladium acetate (Pd(OAc)2, palladium trifluoracetate (Pd(TFA)2), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)- palladium(II) dichloride (PdCl2(CH3CN)2), cyclopentadienyl allyl palladium, allylpalladium(II) chloride dimer (Pd(allyl)Cl)2), (2-butenyl)chloropalladium dimer, (2- methylallyl) palladium(II) chloride dimer, palladium(1-phenylallyl)chloride dimer,(p-tert- butylindenyl) palladium(II) chloride dimer, di-μ-chlorobis[2′-(amino-N)[1,1′-biphenyl]-2- yl-C]dipalladium(II), di-μ-mesylbis[2′-(amino-N)[1,1′-biphenyl]-2-yl-C]dipalladium(II), di-μ-mesylbis[2′-(methylamino-N)[1,1′-biphenyl]-2-yl-C]dipalladium(II), and di-μ- chlorobis[2-[(dimethylamino)methyl]phenyl-C,N]dipalladium(II). Examples of ligands that form palladium catalysts in situ in combination with a palladium source described above include: mono or diphosphines such as PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf. The term “salt” as used herein refers to any kind of salts formed by reacting the compounds disclosed herein with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. Where the compounds disclose herein contain a free acidic moiety, salts may also be prepared by addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like. Manufacturing Process In a first aspect, the present invention provides a process for manufacturing compound 3, or a salt thereof,
Figure imgf000005_0001
3 comprising: (a) reacting aryl bromide 1 +
Figure imgf000005_0002
with (4-carbomethoxyphenyl)boronic acid (2) in the presence of a palladium catalyst and a base, to afford said compound 3. In a further aspect, the present invention provides a process for manufacturing compound 3, or a salt thereof,
Figure imgf000006_0001
3 comprising: (a) reacting aryl bromide 1 +
Figure imgf000006_0003
with (4-carbomethoxyphenyl)boronic acid (2)
Figure imgf000006_0002
in the presence of a palladium catalyst and a base in an aromatic solvent, to afford said compound 3; wherein said palladium catalyst is selected from: i) a preformed catalyst selected from Pd(PPh3)4, Pd(L1)2, [Pd(L1)XCl], [Pd(L1)X]trifluoromethanesulfonate, [Pd(L1)(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L1)(2-(2′-amino-1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2′- methylamino-1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2- aminoethyl)phenyl)Cl], Pd(L2)Cl2, Pd(L2)2Cl2, and [PdI(L3)]2; wherein X is selected from allyl, 2-butenyl, 2-methylallyl, 1-phenylallyl, p-tert- butylindenyl; L1 is selected from PBu3, AmPhos, CPhos, RuPhos, and SPhos; L2 is selected from PtBu3, AmPhos, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3)2, dppf, dcypf, dippf, and dtbpf; and L3 is selected from PtBu3, AmPhos; and ii) a catalyst that is formed in situ from: iia) a palladium source selected from palladium bis(dibenzylideneacetone) (Pd(dba)2), (Pd2(dba)3), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), palladium acetate (Pd(OAc)2, palladium trifluoracetate (Pd(TFA)2), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)-palladium(II) dichloride (PdCl2(CH3CN)2), cyclopentadienyl allyl palladium, allylpalladium(II) chloride dimer (Pd(allyl)Cl)2), (2-butenyl)chloropalladium dimer, (2- methylallyl) palladium(II) chloride dimer, palladium(1- phenylallyl)chloride dimer,(p-tert-butylindenyl) palladium(II) chloride dimer, di-μ-chlorobis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(methylamino-N)[1,1′-biphenyl]-2- yl-C]dipalladium(II), and di-μ-chlorobis[2- [(dimethylamino)methyl]phenyl-C,N]dipalladium(II); and iib) a ligand selected from mono- and diphosphines, in particular a ligand selected from PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf; and said base is selected from inorganic bases and alcoholates, preferably wherein said base is selected from Na2CO3, Ba(OH)2, K3PO4, Cs2CO3, K2CO3, TlOH, KF, CsF, Bu4F, and NaOH, more preferably wherein said base is K3PO4 or K2CO3. Suzuki coupling of aryl bromide 1 with (4-carbomethoxyphenyl)boronic acid (2) instead of with (4-(tert-Butoxycarbonyl)phenyl)boronic acid as described in WO2019206853 affords the new intermediate 3, which can be partially deprotected under basic conditions to afford new intermediate 4 (vide infra). This is in contrast to the gobal deprotection under acidic conditions (trifluoroacetic acid) described in WO2019206853. Importantly, new intermediate 4 is crystalline and can thus be conveniently purified by crystallization, replacing the need for chromatography as described in WO2019206853. In one embodiment of step (a) of the process according to the invention, said palladium catalyst is selected from: i) a preformed catalyst selected from Pd(PPh3)4, Pd(L1)2, [Pd(L1)XCl], [Pd(L1)X]trifluoromethanesulfonate, [Pd(L1)(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L1)(2-(2′-amino-1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2′-methylamino- 1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2-aminoethyl)phenyl)Cl], Pd(L2)Cl2, Pd(L2)2Cl2, and [PdI(L3)]2; wherein X is selected from allyl, 2-butenyl, 2- methylallyl, 1-phenylallyl, p-tert-butylindenyl; L1 is selected from PBu3, AmPhos, CPhos, RuPhos, and SPhos; L2 is selected from PtBu3, AmPhos, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3)2, dppf, dcypf, dippf, and dtbpf; and L3 is selected from PtBu3, AmPhos; and ii) a catalyst that is formed in situ from: iia) a palladium source selected from palladium bis(dibenzylideneacetone) (Pd(dba)2), (Pd2(dba)3), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), palladium acetate (Pd(OAc)2, palladium trifluoracetate (Pd(TFA)2), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)-palladium(II) dichloride (PdCl2(CH3CN)2), cyclopentadienyl allyl palladium, allylpalladium(II) chloride dimer (Pd(allyl)Cl)2), (2- butenyl)chloropalladium dimer, (2-methylallyl) palladium(II) chloride dimer, palladium(1-phenylallyl)chloride dimer,(p-tert-butylindenyl) palladium(II) chloride dimer, di-μ-chlorobis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(methylamino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), and di-μ-chlorobis[2-[(dimethylamino)methyl]phenyl- C,N]dipalladium(II); and iib) a ligand selected from mono- and diphosphines, in particular a ligand selected from PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p- C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf. In one embodiment of step (a) of the process according to the invention, said palladium catalyst is selected from Pd(PPh3)4, Pd(L1)2, [Pd(L1)XCl], [Pd(L1)X]trifluoromethanesulfonate, [Pd(L1)(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L1)(2-(2′- amino-1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2′-methylamino-1,1′- biphenyl)]methanesulfonate, [Pd(L1)(2-(2-aminoethyl)phenyl)Cl], Pd(L2)Cl2, Pd(L2)2Cl2, and [PdI(L3)]2; wherein X is selected from allyl, 2-butenyl, 2-methylallyl, 1-phenylallyl, p- tert-butylindenyl; L1 is selected from PBu3, AmPhos, CPhos, RuPhos, and SPhos; L2 is selected from PtBu3, AmPhos, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3)2, dppf, dcypf, dippf, and dtbpf; and L3 is selected from PtBu3, AmPhos. In one embodiment of step (a) of the process according to the invention, said palladium catalyst is formed in situ from: i) a palladium source selected from palladium bis(dibenzylideneacetone) (Pd(dba)2), (Pd2(dba)3), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), palladium acetate (Pd(OAc)2, palladium trifluoracetate (Pd(TFA)2), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)-palladium(II) dichloride (PdCl2(CH3CN)2), cyclopentadienyl allyl palladium, allylpalladium(II) chloride dimer (Pd(allyl)Cl)2), (2-butenyl)chloropalladium dimer, (2-methylallyl) palladium(II) chloride dimer, palladium(1-phenylallyl)chloride dimer,(p-tert- butylindenyl) palladium(II) chloride dimer, di-μ-chlorobis[2′-(amino-N)[1,1′- biphenyl]-2-yl-C]dipalladium(II), di-μ-mesylbis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(methylamino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), and di-μ-chlorobis[2-[(dimethylamino)methyl]phenyl- C,N]dipalladium(II); and ii) a ligand selected from mono- and diphosphines. In a preferred embodiment, said mono- and diphosphine ligands are selected from PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf. In a preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is selected from Pd(PPh3)4, CPhosPdG3, Pd2(dba)3 + CPhos, and PdCl2(dtbpf). It has been found that the palladium catalyst PdCl2(dtbpf) works particularly well in the Suzuki coupling according to the invention. Thus, the Suzuki coupling with PdCl2(dtbpf) requires only a very low catalyst loading (2 mol% or less) and a small excess of boronic acid 2, which results in reduced amount of contamination of the final product with palladium and organic impurities, reduced cost and reduced waste. Those are all important aspects when manufacturing chemicals on an industrial scale, especially when manufacturing pharmaceutical products. Thus, in a particularly preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is PdCl2(dtbpf). In one embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 1 mol% to 10 mol% relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 1 mol% to 5 mol% relative to aryl bromide 1. In a preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 1 mol% to 3 mol% relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is present in an amount of 2 mol% relative to aryl bromide 1. In a preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is PdCl2(dtbpf) and is present in an amount of 1 mol% to 10 mol% relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is PdCl2(dtbpf) and is present in an amount of 1 mol% to 5 mol% relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is PdCl2(dtbpf) and is present in an amount of 1 mol% to 3 mol% relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, said palladium catalyst is PdCl2(dtbpf) and is present in an amount of 2 mol% relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, said base is selected from inorganic bases and alcoholates. In a preferred embodiment of step (a) of the process according to the invention, said base is selected from Na2CO3, Ba(OH)2, K3PO4, Cs2CO3, K2CO3, TlOH, KF, CsF, Bu4F, and NaOH. In a preferred embodiment of step (a) of the process according to the invention, said base is selected from K3PO4 and K2CO3. In a particularly preferred embodiment of step (a) of the process according to the invention, said base is K3PO4. In a particularly preferred embodiment of step (a) of the process according to the invention, said base is K2CO3. In one embodiment of step (a) of the process according to the invention 1 to 4 equivalents of said base relative to aryl bromide 1 are used. In a preferred embodiment of step (a) of the process according to the invention 1 to 3 equivalents of said base relative to aryl bromide 1 are used. In a further preferred embodiment of step (a) of the process according to the invention 1 to 2 equivalents of said base relative to aryl bromide 1 are used. In a particularly preferred embodiment of step (a) of the process according to the invention 1.5 equivalents of said base relative to aryl bromide 1 are used. One advantage of the Suzuki coupling of process step (a) according to the invention is that it performs very well in toluene, as opposed to the toxic dioxane described in WO2019206853. This is of particular importance when conducting the reaction on an industrial scale and in view of the fact that the final antibiotic product of formula (I) is for administration to mammals, where traces of toxic solvents are not acceptable. Thus, in one embodiment of step (a) of the process according to the invention, step (a) is conducted in an aromatic solvent. In one embodiment, said aromatic solvent is selected from toluene, xylenes (o-xylene, p- xylene, m-xylene or a mixture thereof), ethylbenzene, anisole, cumene, and cymene. In a preferred embodiment said aromatic solvent is toluene. It was found that the methyl ester moiety of boronic acid building block 2 is prone to hydrolysis under the reaction conditions used. However, it was surprisingly found that adding water to the reaction mixture prevents said hydrolysis, allowing to employ fewer equivalents of this building block. Thus, in one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 1 to 30 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 1 to 20 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 5 to 25 equivalents of water relative to aryl bromide 1. In a preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 10 to 25 equivalents of water relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 12.5 to 25 equivalents of water relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 25 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 5 to 15 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 10 to 15 equivalents of water relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of 12.5 equivalents of water relative to aryl bromide 1. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-8 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-7 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. In a preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 3-6 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. In one embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-5 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. In a preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 2-4 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. In a particularly preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 6 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. In a particularly preferred embodiment of step (a) of the process according to the invention, the process is conducted in the further presence of water, wherein the water is continuously added over a period of 3 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. As mentioned above, the new Suzuki coupling according to the invention allows the use of less equivalents of boronic acid 2 compared to the amound of boronic acid that is used in the process described in WO2019206853. Thus, in one embodiment of step (a) of the process according to the invention, 1 to <1.5 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a preferred embodiment of step (a) of the process according to the invention, 1 to 1.4 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1 to 1.3 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1.05 to 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1 to 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a further preferred embodiment of step (a) of the process according to the invention, 1 to 1.1 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1. In a particularly preferred embodiment of step (a) of the process according to the invention, 1.05 equivalents of boronic acid 2 are used relative to aryl bromide 1. If desired, the level of palladium contamination of compound 3 may be reduced, typically to a level of <10 ppm, by treating compound 3 with N-acetylcysteine or ammonium pyrrolidinedithiocarbamate in situ. Thus, in one embodiment, the process for manufacturing compound 3, or a salt thereof, according to the invention optionally further comprises: (b) adding ammonium pyrrolidinedithiocarbamate or an aqueous solution of N- acetylcysteine to the reaction mixture obtained from step (a). In one embodiment, the process for manufacturing compound 3, or a salt thereof, according to the invention optionally further comprises: (b) adding an aqueous solution of N-acetylcysteine to the reaction mixture obtained from step (a). In one embodiment, the process for manufacturing compound 3, or a salt thereof, according to the invention optionally further comprises: (b) adding ammonium pyrrolidinedithiocarbamate to the reaction mixture obtained from step (a). In a further aspect, the present invention provides a process for manufacturing compound 4, or a salt thereof,
Figure imgf000015_0001
comprising steps (a) and (b) as described herein, and further comprising: (c) reacting compound 3 described herein with sodium hydroxide to afford said compound 4. In one embodiment, step (c) is performed in a solvent being an alcohol, preferably in methanol. In a further aspect, the present invention provides a process for manufacturing compound 4, or a salt thereof, comprising steps (a) and (b) as described herein, and further comprising: (c) reacting compound 3 according to claim 1 with 2 to 10 equivalents, preferably 3 to 8 equivalents, more preferably 4 to 7 equivalents, in particular 7 equivalents of sodium hydroxide to afford said compound 4, wherein said sodium hydroxide is added as a 5% w/w to 30% w/w, preferably 10% w/w to 20% w/w, in particular a 16% w/w aqueous solution to a solution of compound 3 in an alcoholic solvent or a mixture of water and an alcoholic solvent. In one embodiment, said alcoholic solvent is methanol. A major advantage of new compound 4 according to the invention is its crystallinity, allowing it to be purified by crystallization. Especially on an industrial scale, crystallization is a convenient means of purification of chemicals, as opposed to other purification techniques, such as chromatography. Thus, in one embodiment, the process for manufacturing compound 4 according to the invention optionally further comprises: (d) crystallizing said compound 4. In a preferred embodiment of step (d) of the process according to the invention, said crystallizing of said compound 4 is crystallizing of said compound 4 from a mixture of an alcohol and acetone. In a preferred embodiment, said alcohol is selected from 2-propanol and 1-propanol. In a particularly preferred embodiment said alcohol is 1-propanol. In a further aspect, the present invention provides a process for manufacturing the compound of formula (I), or a pharmaceutically acceptable salt thereof, comprising process steps (a)-(d) described herein, and further comprising: (e) reacting compound 4 described herein with an acid, to afford said compound of formula (I). In a preferred embodiment of step (e) of the process according to the invention, said acid is hydrochloric acid. In one embodiment, step (e) is performed in a solvent mixture selected from acetone/water, THF/water, and acetonitrile/water. In one embodiment, 2 to 6 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In a preferred embodiment, 3 to 5 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In a further preferred embodiment, 4 to 5 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In a further preferred embodiment, 3.5 to 4.5 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In a particularly preferred embodiment, 4 to 4.1 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In a further particularly preferred embodiment, 4 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In a further particularly preferred embodiment, 4.1 equivalents of acid relative to compound 4 are used in step (e) of the process according to the invention. In one embodiment, step (e) of the process according to the invention is performed between room temperature and reflux. In a preferred embodiment, step (e) of the process according to the invention is performed between 30 °C and reflux. In a further preferred embodiment, step (e) of the process according to the invention is performed between 35 °C and 65 °C. In a particularly preferred embodiment, step (e) of the process according to the invention is performed between 35 °C and 60 °C. In a further aspect, the present invention provides the use of the process for manufacturing compound 3 described herein in the manufacture of the compound of formula (I). In a further aspect, the present invention provides the use of the process for manufacturing compound 4 described herein in the manufacture of the compound of formula (I). Compounds of the Invention The present invention relates to certain synthetic intermediates that are useful for manufacturing the novel antibiotic of formula (I) described herein. The present invention also relates to certain compounds when manufactured according to the novel chemical processes described herein. In more detail, in one aspect, the present invention provides a compound, which is tert- butyl 3-[[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-22-(4-methoxycarbonylphenyl)-16-methyl-12,15,18-trioxo- 2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-17- yl]methyl]indole-1-carboxylate (3), or a salt thereof . In a further aspect, the present invention provides a compound, which is 4-[(11S,14S,17S)- 14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert-butoxycarbonylamino)propyl]-17-(1H- indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22-yl]benzoic acid (4), or a salt thereof
Figure imgf000019_0001
. In a further aspect, the present invention relates to compound 3 when manufactured according to the processes for manufacturing compound 3 described herein. In a further aspect, the present invention relates to compound 3 when manufactured according to the processes for manufacturing compound 3 described herein. In a further aspect, the present invention relates to the compound of formula (I) when manufactured according to the processes for manufacturing the compound of formula (I) described herein. In a further aspect, the present invention relates to the use of compound 3 described herein in the manufacture of the compound of formula (I). In a further aspect, the present invention relates to the use of compound 4 described herein in the manufacture of the compound of formula (I). Examples The invention will be more fully understood by reference to the following examples. The claims should not, however, be construed as limited to the scope of the examples. The following abbreviations are used in the present text: PdCl2(dtbpf) = [1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (CAS 95408-45-0); HCl = hydrochloric acid; PPh3 = triphenylphosphine; PtBu3 = tri-tert- butylphosphine; PAd3 = tri(1-adamantyl)phosphine; AmPhos = (4-(N,N- dimethylamino)phenyl)di-tert-butyl phosphine; cataCXiumA = di(1-adamantyl)-n- butylphosphine; PtBu2Bu = di-t-butyl(n-butyl)phosphine; PtBu2Ph = di-t- butyl(phenyl)phosphine; PtBu2-p-C6H4CF3 = di-t-butyl(4-trifluoromethyl phenyl)phosphine; cataCXium POMeCy = 1-(2-Methoxyphenyl)-2- (dicyclohexylphosphino)pyrrole; CPhos = 2-dicyclohexylphosphino-2′,6′-bis(N,N- dimethylamino)biphenyl; RuPhos = 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl; SPhos = 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl; dppf = 1,1′-Ferrocenediyl- bis(diphenylphosphine); dcypf = 1,1′-Ferrocenediyl-bis(dicyclohexylphosphine); dippf = 1,1′-Ferrocenediyl-bis(diisopropylphosphine); dtbpf = 1,1′-Bis(di-tert- butylphosphino)ferrocene; Pd(PPh3)4 = tetrakis (triphenyl-phosphino) palladium; CPhosPdG3 = [(2-Dicyclohexylphosphino-2′,6′-bis(N,N-dimethylamino) -1,1′-biphenyl)- 2-(2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate; Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(0). Example 1 Preparation of 4-[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia- 4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22- yl]benzoic acid To a dry, Ar-flushed flask were charged 3-[[(11S,14S,17S)-22-bromo-14-[4-(tert- butoxycarbonylamino)butyl]-11-[3-(tert-butoxycarbonylamino)propyl]-12,15,18-triketo- 16-methyl-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23- hexaen-17-yl]methyl]indole-1-carboxylic acid tert-butyl ester (1) (30.0 g, 28.57 mmol, 1.0 eq), tripotassium phosphate (9.10 g , 42.85 mmol, 1.5 eq) and toluene (300 ml, 10 vol). The mixture was degassed and heated to 90°C. To the hot mixture were added (4- carbomethoxyphenyl)boronic acid (2) (5.4 g, 30.00 mmol, 1.05 eq) and PdCl2(dtbpf) (372 mg, 0.571 mmol, 0.02 eq). To the resulting suspension water (6.43 g, 357.1 mmol, 12.5 eq) was charged over 3 h via syringe pump. The mixture was stirred for 4h. The mixture was cooled to 60°C and 9% w/w aq. N-acetylcysteine was added. The mixture was stirred for 1h at 60°C, then the phases were split. The organic phase was extracted with water. The organic layer was treated with activated charcoal at room temperature. The mixture was distilled under reduced pressure an the solvent was swapped to methanol and concentrated to a final volume of 80 ml. Methanol (221 ml, 7.4 vol) and water (70 ml, 2.3vol) are added. The mixture is heated to 50°C and 32% w/w aq. sodium hydroxide (25.0 g, 200.0 mmol, 7.0 eq) is added. The mixture is stirred for 5h and then cooled to 20°C. Methanol is distilled off under reduced pressure. Ethyl acetate (250 ml, 8.3 vol) and a solution of citric acid (27.8 g) in water (60 ml, 2 vol) are charged to the residue at room temperature. The organic phase is extracted with a solution of sodium bicarbonate (4.88 g) in water (150 ml) and then with water (150 ml). The organic phase is concentrated to 3 vol under reduced pressure. The solvent is switched to 1-propanol to a final volume of ca.3.3 vol. The residue is heated to 60°C. Acetone (198 g, 250 ml, 8.33 vol) is added in 1.5h. The resulting suspension is cooled to 20°C in 5h. The solids are recovered by suction filtration and rinsed with a solution of 1-propanol (20 g) and acetone (60 g) and dried under reduced pressure.23.1 g (81.4% yield) of crude 4-[(11S,14S,17S)-14-[4-(tert- butoxycarbonylamino)butyl]-11-[3-(tert-butoxycarbonylamino)propyl]-17-(1H-indol-3- ylmethyl)-12,15,18-triketo-16-methyl-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22-yl]benzoic acid (4) as off-white solid is obtained. Example 1a Preparation of 4-[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia- 4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22- yl]benzoic acid
Figure imgf000022_0001
To a dry, Ar-flushed flask were charged 3-[[(11S,14S,17S)-22-bromo-14-[4-(tert- butoxycarbonylamino)butyl]-11-[3-(tert-butoxycarbonylamino)propyl]-12,15,18-triketo- 16-methyl-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23- hexaen-17-yl]methyl]indole-1-carboxylic acid tert-butyl ester (1) (5.0 g, 4.76 mmol, 1.0 eq), potassium carbonate (0.987 g , 7.14 mmol, 1.5 eq) and toluene (50 ml, 10 vol). The mixture was degassed and heated to 90°C. To the hot mixture were added (4- carbomethoxyphenyl)boronic acid (2) (1.0 g, 5.56 mmol, 1.2 eq) and toluene (25 ml, 5 vol). The mixture is distilled under reduced pressure, until 25 ml distillate are collected. PdCl2(dtbpf) (62 mg, 0.095 mmol, 0.02 eq) is added and the mixture is stirred ca.30 min at 85-90°C. Water (2.14 g, 119.03 mmol, 25.0 eq) was charged over 6 h via syringe pump. The mixture was stirred for at least 2h. Ammonium pyrrolidinedithiocarbamate (237 mg, 1.43 mmol, 0.3 eq) is added. The mixture was stirred for at least 1 h at 85-90°C, then the phases were split. The organic phase was extracted with water. The organic layer was distilled under reduced pressure and methanol (12.5 ml, 2.5 vol) is added. The mixture is cooled to 40°C. A 16% w/w aqueous soludion of sodium hydroxide (8.33 g, 33.33 mmol, 7.0 eq) is added. The mixture is stirred for at least 5 h and then cooled to 20°C. A 35% w/w aqueous solution of citric acid (13.07 g, 23.81 mmol, 5.0 eq) is charged to the residue at 20°C and the mixture is distilled under reduced pressure. The residue is extracted with ethyl acetate. The organic phase is extracted with water, dried over sodium sulfate and diluted with ethyl acetate (15 ml). The solution is heated to 60°C and stirred for ca.1h. The resulting suspension is cooled in 12h to 0°C and stirred at least 2h. The solids are recovered by suction filtration and rinsed with cold ethyl acetate.3.2 g (80.4% yield) of 4-[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2- thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22- yl]benzoic acid (4) as off-white solid is obtained. Example 2 Preparation of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3- ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22-yl]benzoic acid
Figure imgf000023_0001
4-[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-11-[3-(tert- butoxycarbonylamino)propyl]-17-(1H-indol-3-ylmethyl)-12,15,18-triketo-16-methyl-2- thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-22- yl]benzoic acid (4) (200 g, 201.78 mmol, 1 eq), tetrahydrofuran (455 ml), and water (320 mL) were charged into a 2000 mL four-necked reaction vessel and stirred at 35°C. A solution of HCl 25% (99.8 mL, 821 mmol, 4.1 eq.) and water (200 mL) was added within 10 minutes at 35 to 50°C. The addition funnel was rinsed with water (50 mL) and the reaction mixture was stirred at 60°C for 4 hours. Following basic workup and crystallization at pH 10, the title compound was obtained as a white powder (158.3 g, 98.5%).

Claims

CLAIMS 1. A compound, which is tert-butyl 3-[[(11S,14S,17S)-14-[4-(tert- butoxycarbonylamino)butyl]-11-[3-(tert-butoxycarbonylamino)propyl]-22-(4- methoxycarbonylphenyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3,5,7,21,23-hexaen-17- yl]methyl]indole-1-carboxylate (3), or a salt thereof
Figure imgf000025_0001
. 2. A compound, which is 4-[(11S,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]- 11-[3-(tert-butoxycarbonylamino)propyl]-17-(1H-indol-3-ylmethyl)-16-methyl- 12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa- 1(25),3,5,7,21,23-hexaen-22-yl]benzoic acid (4), or a salt thereof
Figure imgf000025_0002
. 3. A process for manufacturing compound 3 according to claim 1, or a salt thereof, comprising: (a) reacting aryl bromide 1 + with (4-carbomethoxyphenyl)boronic acid (2)
Figure imgf000026_0001
in the presence of a palladium catalyst and a base in an aromatic solvent, to afford said compound 3; wherein said palladium catalyst is selected from: i) a preformed catalyst selected from Pd(PPh3)4, Pd(L1)2, [Pd(L1)XCl], [Pd(L1)X]trifluoromethanesulfonate, [Pd(L1)(2-(2′-amino-1,1′-biphenyl)Cl]; [Pd(L1)(2-(2′-amino-1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2′- methylamino-1,1′-biphenyl)]methanesulfonate, [Pd(L1)(2-(2- aminoethyl)phenyl)Cl], Pd(L2)Cl2, Pd(L2)2Cl2, and [PdI(L3)]2; wherein X is selected from allyl, 2-butenyl, 2-methylallyl, 1-phenylallyl, p-tert- butylindenyl; L1 is selected from PBu3, AmPhos, CPhos, RuPhos, and SPhos; L2 is selected from PtBu3, AmPhos, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3)2, dppf, dcypf, dippf, and dtbpf; and L3 is selected from PtBu3, AmPhos; and ii) a catalyst that is formed in situ from: iia) a palladium source selected from palladium bis(dibenzylideneacetone) (Pd(dba)2), (Pd2(dba)3), bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh3)2Cl2), palladium acetate (Pd(OAc)2, palladium trifluoracetate (Pd(TFA)2), palladium chloride (PdCl2), palladium bromide (PdBr2),palladium iodide (PdI2), palladium bis acetylacetonate (Pd(acac)2), (Pd(PPh3)4), bis(acetonitrile)-palladium(II) dichloride (PdCl2(CH3CN)2), cyclopentadienyl allyl palladium, allylpalladium(II) chloride dimer (Pd(allyl)Cl)2), (2-butenyl)chloropalladium dimer, (2- methylallyl) palladium(II) chloride dimer, palladium(1- phenylallyl)chloride dimer,(p-tert-butylindenyl) palladium(II) chloride dimer, di-μ-chlorobis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(amino-N)[1,1′-biphenyl]-2-yl- C]dipalladium(II), di-μ-mesylbis[2′-(methylamino-N)[1,1′-biphenyl]-2- yl-C]dipalladium(II), and di-μ-chlorobis[2- [(dimethylamino)methyl]phenyl-C,N]dipalladium(II); and iib) a ligand selected from mono- and diphosphines, in particular a ligand selected from PtBu3, PAd3, AmPhos, cataCXiumA, PtBu2Bu, PtBu2Ph, PtBu2-p-C6H4CF3, cataCXium POMeCy, CPhos, RuPhos, SPhos, dppf, dcypf, dippf, and dtbpf; and said base is selected from inorganic bases and alcoholates, preferably wherein said base is selected from Na2CO3, Ba(OH)2, K3PO4, Cs2CO3, K2CO3, TlOH, KF, CsF, Bu4F, and NaOH, more preferably wherein said base is K3PO4 or K2CO3. 4. The process according to claim 3, wherein said palladium catalyst is present in an amount of 1 mol% to 10 mol%, preferably 1 mol% to 5 mol%, more preferably 1 mol% to 3 mol%, most preferably 2 mol% relative to aryl bromide 1. 5. The process according to claim 3 or 4, wherein 1 to 4 equivalents, preferably 1 to 3 equivalents, more preferably 1 to 2 equivalents, most preferably 1.5 equivalents of said base relative to aryl bromide 1 are used. 6. The process according to any one of claims 3 to 5, wherein said aromatic solvent is selected from toluene, xylenes (o-xylene, p-xylene, m-xylene or a mixture thereof), ethylbenzene, anisole, cumene, and cymene. 7. The process according to claim 6, wherein said aromatic solvent is toluene. 8. The process according to any one of claims 3 to 7, wherein the process is conducted in the further presence of water, preferably 1 to 30 equivalents, more preferably 5 to 25 equivalents, most preferably 10 to 25 equivalents, in particular 12.5 to 25 equivalents of water relative to aryl bromide 1. 9. The process according to claim 8, wherein the water is continuously added over a period of 2-8 h, preferably over a period of 2-7 h, most preferably over a period of 3- 6 h to the reaction mixture comprising aryl bromide 1, boronic acid 2, palladium catalyst and base. 10. The process according to any one of claims 3 to 9, wherein 1 to <1.5 equivalents, preferably 1 to 1.3 equivalents, more preferably 1 to 1.2 equivalents, more preferably 1.05 to 1.2 equivalents of boronic acid 2 are used relative to aryl bromide 1. 11. The process according to any one of claims 3 to 10, optionally further comprising: (b) adding ammonium pyrrolidinedithiocarbamate or an aqueous solution of N- acetylcysteine to the reaction mixture obtained from step (a). 12. A process for manufacturing compound 4 according to claim 2, or a salt thereof, comprising the process according to any one of claims 3 to 11, and further comprising: (c) reacting compound 3 according to claim 1 with 2 to 10 equivalents, preferably 3 to 8 equivalents, more preferably 4 to 7 equivalents, in particular 7 equivalents of sodium hydroxide to afford said compound 4, wherein said sodium hydroxide is added as a 5% w/w to 30% w/w, preferably 10% w/w to 20% w/w, in particular a 16% w/w aqueous solution to a solution of compound 3 in an alcoholic solvent or a mixture of water and an alcoholic solvent. 13. The process according to claim 12, wherein said alcoholic solvent in step (c) is methanol. 14. The process according to claim 12 or 13, optionally further comprising: (d) crystallizing said compound 4, preferably from a mixture of 1-propanol and acetone. 15. A process for manufacturing the compound of formula (I), or a pharmaceutically acceptable salt thereof, comprising the process according to any one of claims 12 to 14, and further comprising: (e) reacting compound 4 according to claim 2 with an acid, preferably with hydrochloric acid, to afford said compound of formula (I). 16. The process according to claim 15, wherein step (e) is performed in a solvent mixture selected from acetone/water, THF/water, and acetonitrile/water. 17. The process according to any one of claims 15 or 16, wherein 2 to 6 equivalents, preferably 3 to 5 equivalents, more preferably 4 to 5 equivalents, more preferably 3.5 to 4.5 equivalents, in particular 4.1 equivalents of acid relative to compound 4 are used in step (e). 18. The process according to any one of claims 15 to 17, wherein the process is performed between room temperature and reflux, preferably between 30 °C and reflux, more preferably between 35 °C and 65 °C, most preferably between 35 °C and 60 °C. 19. Compound 3 according to claim 1, or a salt thereof, when manufactured according to the process of any one of claims 3 to 11. 20. Compound 4 according to claim 2, or a salt thereof, when manufactured according to the process of any one of claims 12 to 14. 21. Compound of formula (I), or a pharmaceutically acceptable salt thereof, when manufactured according to the process of any one of claims 15 to 18. 22. Use of the process according to any one of claims 3 to 14 in the manufacture of the compound of formula (I),
Figure imgf000030_0001
or a pharmaceutically acceptable salt thereof. 23. Use of compound 3 according to claim 1 in the manufacture of the compound of formula (I). 24. Use of compound 4 according to claim 2 in the manufacture of the compound of formula (I). 25. The invention as described hereinbefore.
PCT/EP2023/071759 2022-08-09 2023-08-07 Process for manufacturing an antibiotic macrocyclic peptide Ceased WO2024033278A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020257003548A KR20250049274A (en) 2022-08-09 2023-08-07 Process for manufacturing antibiotic macrocyclic peptides
IL317277A IL317277A (en) 2022-08-09 2023-08-07 Process for manufacturing an antibiotic macrocyclic peptide
AU2023322412A AU2023322412A1 (en) 2022-08-09 2023-08-07 Process for manufacturing an antibiotic macrocyclic peptide
JP2025507242A JP2025526023A (en) 2022-08-09 2023-08-07 Manufacturing process for antibacterial macrocyclic peptides
EP23753892.1A EP4568984A1 (en) 2022-08-09 2023-08-07 Process for manufacturing an antibiotic macrocyclic peptide
CN202380057957.7A CN119677765A (en) 2022-08-09 2023-08-07 Method for making antibiotic macrocyclic peptides
MX2025001261A MX2025001261A (en) 2022-08-09 2025-01-30 Process for manufacturing an antibiotic macrocyclic peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22189412.4 2022-08-09
EP22189412 2022-08-09

Publications (1)

Publication Number Publication Date
WO2024033278A1 true WO2024033278A1 (en) 2024-02-15

Family

ID=82851819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/071759 Ceased WO2024033278A1 (en) 2022-08-09 2023-08-07 Process for manufacturing an antibiotic macrocyclic peptide

Country Status (9)

Country Link
EP (1) EP4568984A1 (en)
JP (1) JP2025526023A (en)
KR (1) KR20250049274A (en)
CN (1) CN119677765A (en)
AU (1) AU2023322412A1 (en)
IL (1) IL317277A (en)
MX (1) MX2025001261A (en)
TW (1) TW202417464A (en)
WO (1) WO2024033278A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072062A1 (en) * 2015-10-27 2017-05-04 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
WO2019206853A1 (en) 2018-04-23 2019-10-31 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072062A1 (en) * 2015-10-27 2017-05-04 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
WO2019206853A1 (en) 2018-04-23 2019-10-31 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WHO DRUG INFORMATION, vol. 36, no. 2, 2022

Also Published As

Publication number Publication date
TW202417464A (en) 2024-05-01
AU2023322412A1 (en) 2024-11-21
MX2025001261A (en) 2025-03-07
IL317277A (en) 2025-01-01
EP4568984A1 (en) 2025-06-18
JP2025526023A (en) 2025-08-07
CN119677765A (en) 2025-03-21
KR20250049274A (en) 2025-04-11

Similar Documents

Publication Publication Date Title
JP7398436B2 (en) Methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7 ] Annelene-2-carboxylate salt and method for producing the same
CN1042102C (en) Carbonylation Catalyst System
CN113906032A (en) Methods for preparing enantiomerically enriched JAK inhibitors
EP4175960A1 (en) Preparation of a pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone derivative and salt thereof
KR20180095894A (en) Metal complex
JP2025016562A (en) Method for producing nitrogen-containing heteroarylcarboxamidoacetic acid derivatives
US7321038B2 (en) Method for the catalytic production of hydrocodone and hydromorphone
US20230348390A1 (en) Method for preparing methyl(s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenylpropionate and salt thereof
WO2006069287A1 (en) Process for making substituted piperidines
WO2024033278A1 (en) Process for manufacturing an antibiotic macrocyclic peptide
WO2008095678A1 (en) Process for the preparation of optically active 2-amino-1-phenylethanols
JP2008505903A (en) Formation of tetrasubstituted enamides and this stereoselective reduction.
JPH0632780A (en) Asymmetric reduction method
CN120359215A (en) Process for preparing quinazolinone derivatives
JP2003522744A (en) Method for producing polycyclic aromatic compound
CN112675920B (en) A class of monochiral center catalysts and methods for preparing and catalytically synthesizing chiral alcohol compounds and chiral α-allyl alcohols
EP2762467B1 (en) Method for producing an optically active 2-arylpiperidinium salt
JP5099830B2 (en) Method for producing dibenzoxepin derivative
CN108290910B (en) N,N-bis(2-dialkylphosphinoethyl)amine-borane complex, method for producing the same, and method for producing a ruthenium complex using the amine as a ligand
US20200165175A1 (en) Process for the preparation of deuterated ethanol from d2o
CN115703806B (en) Phosphine ligand of pyrazole-amide framework, and preparation method and application thereof
WO2008044702A1 (en) Process for production of azabicycloalkanol derivative
Ku et al. A Highly Efficient Synthesis of a Naphthalenoid Histamine‐3 Antagonist
US20100261905A1 (en) Ruthenium Catalysts for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof
TW202542111A (en) A method for preparing a phenylpiperidine derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753892

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023322412

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023322412

Country of ref document: AU

Date of ref document: 20230807

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 317277

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/001261

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 202380057957.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2025507242

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025002409

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: MX/A/2025/001261

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2023753892

Country of ref document: EP

Ref document number: 2025101730

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023753892

Country of ref document: EP

Effective date: 20250310

WWP Wipo information: published in national office

Ref document number: 202380057957.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11202500789T

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202500789T

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 1020257003548

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023753892

Country of ref document: EP

Ref document number: 2025101730

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112025002409

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250206